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Abstract 
 
Functional analysis of the -1087 single nucleotide polymorphism in the IL-10 
promoter region. 
 
Lena Larsson 
Department of Periodontology, Institute of Odontology, the Sahlgrenska Academy at University of 
Gothenburg 
 
Interleukin (IL) 10 is recognized as a pro-inflammatory cytokine that promotes B cell 
proliferation. The objectives of the present series of studies were to analyze (i) 
differences in transcription factor binding to the -1087 IL-10 gene polymorphism in B 
cells, (ii) the influence of the A to G nucleotide transition on IL-10 and Sp1 gene 
expression in B cells, (iii) differences in Sp1 expression in periodontitis lesions from 
GG and AA genotype subjects and (iv) epigenetic modifications around the -1087 site 
and their influence on IL-10 gene expression. Using B cells from subjects with GG 
and AA genotypes it was demonstrated that PU.1 and Spi-B bound to both G- and A-
alleles, whereas Sp1 only bound to the G-allele at -1087. LPS-stimulation resulted in a 
larger increase in IL-10 and Sp1 gene expression in B cells with GG than in B cells 
with AA genotypes (study I and II). Sp1 was present in B cells in periodontitis lesions 
and subjects with the GG genotype exhibited larger proportions of Sp1-positive cells 
and expressed larger amounts of Sp1 mRNA and protein in the lesion than AA 
genotype subjects (study III). Epigenetic modifications influenced IL-10 gene 
expression and differences in epigenetic modifications in the promoter region were 
found between GG and AA genotypes (study IV). The results found in the present 
series indicate that Sp1 is important in the regulation of IL-10.  
 
 
Key words: IL-10, B cells, Sp1, transcription factors, gene expression. 
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Preface 
 
The present thesis is based on the following publications, which will be referred to in 
the text by their Roman numerals. 
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The Sp1 transcription factor binds to the G-allele of the -1087 IL-10 gene 
polymorphism and enhances transcriptional activation. Genes and Immunity 
10:280-284. 
 
II. Larsson L, Rymo L & Berglundh T (2010). Sp1  binds  to the  G allele  of  the  
-1087 polymorphism in the IL-10 promoter and promotes IL-10 mRNA 
transcription and protein production. Genes and Immunity 11:181-187. 
 
III. Larsson L, Thorbert-Mros S, Rymo L & Berglundh T (2010). IL-10 genotypes 
of the -1087 single nucleotide polymorphism influence Sp1 expression in 
periodontitis lesions. Submitted.    
 
IV. Larsson L, Thorbert-Mros S, Rymo L & Berglundh T (2010). Influence of 
epigenetic modifications in the IL-10 promoter on IL-10 gene expression. 
Submitted. 
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List of abbreviations 
 
APC antigen presenting cells 
AP1 activator protein 1 
5-aza 5-aza-deoxycytidine 
BC bone crest 
BCR B cell receptor 
bp base pair 
CD cluster of differentiation 
cDNA complementary DNA 
C/EBP CCAAT-Enhancer-Binding Protein 
CEJ cemento-enamel junction 
ChIP chromatin immunoprecipitation 
cMaf c-maf musculoaponeurotic fibrosarcoma oncogen homolog 
CpG cytosine and guanine separated by a phosphate 
Ct threshold cycle 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphates 
ddNTP dideoxyribonucleoside triphosphates 
EBV Epstein-Barr virus 
ELISA enzyme-linked immunosorbent assay 
EMSA electrophoretic mobility shift assay 
ERK extracellular signal-regulated kinase 
ETS E-twenty-six specific 
FACS fluorescence activated cell sorting 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HDACi HDAC inhibitor 
HRM high resolution melt curve analysis 
HRP horseradish peroxidase  
HSC hematopoietic stem cell 
IFN interferon 
Ig immunoglobulin 
IHC immunohistochemistry 
IL interleukin 
JNK c-Jun NH2-terminal kinase 
kb kilo base pair 
LBP lipopolysaccharide-binding protein 
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LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MD2 myeloid differentiation-2 protein 
MHC II Major histocompatibility complex II 
MMP matrix metalloproteinase 
mRNA messenger RNA 
NFκB nuclear factor κB 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PLA proximity ligation assay 
PMN polymorphonuclear 
PU.1 Purine-rich box 1 
RCA rolling circle amplification 
RCP rolling circle product 
RNA ribonucleic acid 
RNA pol II RNA polymerase II 
RNAi RNA interference 
siRNA short interfering RNA 
SLE systemic lupus erythematosus 
SL2 Schneider’s Drosophila line 2 
SNP single nucleotide polymorphism 
Sp1 SV40 promoter factor 1/ specificity protein 1 
Spi-B Spleen focus-forming virus integration site 
Stat Signal transducer and activator of transcription 
TBP TATA-box binding protein 
Th T helper cells 
TLR Toll like receptor 
TNF tumor necrosis factor 
TSA trichostatin A 
VPA valproic acid 
XKLF Krüppel-like factor 
  
Introduction 
  13 
 
Introduction 
 
The immune system is a complex process involving several cell types and cytokines. 
The host response to bacteria or viruses is regulated by different signaling pathways, 
which in turn is influenced by genetic and also epigenetic factors. This may explain 
differences in susceptibility to a disease between subjects and, hence identifying target 
molecules that promote susceptibility is important. Research on the immune response 
to periodontal pathogens has identified B cells and the cytokine Interleukin (IL) 10 as 
important components in the perpetuation process of the chronic inflammatory 
lesion. The aim of this thesis was to analyze the influence of genetic and epigenetic 
factors on the regulation of B cell-derived IL-10 gene expression. 
 
Periodontitis 
Periodontitis is an infectious disease caused by microorganisms colonizing the tooth 
surface at or below the gingival margin (Socransky & Haffajee 2003). As a result an 
inflammatory cell infiltrate develops in gingival tissues and in susceptible individuals 
this inflammatory lesion may progress and lead to loss of connective tissue attachment 
and alveolar bone (Page & Kornman 1997). Chronic periodontitis is a common 
disorder and severe forms of the disease occur in about 10% of an adult population 
(Hugoson et al. 2008). Several morphological changes occur in the tissues during the 
development of the periodontitis lesion. A central part is the apical migration of the 
junctional epithelium and the formation of the pocket epithelium (Bartold & 
Narayanan 2006). The periodontitis lesion contains large proportions of inflammatory 
cells and vascular structures.  
 
The host response to pathogens involves reactions of the innate and the adaptive 
immune systems. The innate host response is the first line defense against pathogens 
and consists of the epithelial barriers, phagocytic cells and proteins, such as the 
complement system and cytokines, which regulate the functions of the cells. In 
contrast to the innate immune system the adaptive host response develops over time 
and has the capacity to recognize and react specifically to different pathogens. The 
cells of the adaptive response are primarily lymphocytes and antigen presenting cells 
(APCs) (Abbas & Lichtman 2005). In periodontitis lesions several cells serve as 
antigen presenting cells; langerhans cells, dendritic cells, macrophages and B cells 
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(Berglundh & Donati 2005). Interaction between activated T cells and B cells lead to B 
cell proliferation and differentiation into plasma cells or memory cells. B cells and 
macrophages act to maintain the inflammatory reaction (Abbas & Lichtman 2005). 
Activation of immune cells results in an increase in the production of pro- and anti-
inflammatory cytokines. Cytokines influence the immune response either by direct 
action or by initiating the production of other cytokines. They also influence the 
signaling of proteins and transcription factors in the regulation of gene expression and 
cellular functions (Bartold & Narayanan 2006). 
 
The most common cell types in periodontitis lesions are B cells and their subset 
plasma cells; together they represent about 68% of the cells in the lesion (Fig 1). The 
proportions of plasma cells and B cells in periodontitis lesions appear to correlate to 
the level of disease severity (Berglundh & Donati 2005). 
 
 
 
 
Fig 1. Distribution of cells in periodontitis lesions; plasma cells, B cells, T helper cells, Cytotoxic T 
cells, polymorphonuclear (PMN) cells, macrophages and other cell types (e.g. mast cells, fibroblasts). 
(Adapted from Berglundh & Donati 2005). 
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B cells 
B cells serve as antigen presenting cells and express MHC class II antigen upon 
stimulation. They are part of antigen recognition and early response mechanisms in 
host defense. B cells are suggested to be the major type of APC in periodontitis lesions 
(Gemmell et al. 2003). B cells develop from pluripotent hematopoietic stem cells 
(HSC) into immature B cells in the bone marrow (Fig 2). Cytokine signaling and 
different transcription factors, including PU.1, are essential in the differentiation of 
HSC into B cells and in the regulation of early B cell lymphopoiesis (Welner et al. 
2008; Busslinger 2004).  The immature B cells go through a tolerance checkpoint 
where cells expressing autoreactive B cells receptors (BCR) will be subjected to 
apoptosis or gene rearrangement of the BCR in order to change specificity. Cells that 
have passed this checkpoint are termed mature B cells and leave the bone marrow. 
The B cells continue to develop in secondary lymphoid organs, in which they go 
through a second tolerance checkpoint (Loder et al. 1999; Rajewsky 1996; Wang et al. 
2007). Surviving B cells circulate between follicles in the spleen, lymph nodes and the 
bone marrow. When they meet a BCR specific antigen they mature into memory B 
cells or plasma cells. 
 
 
Fig 2. Maturation of B cells from hematopoietic stem cells. 
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Conventional B cells that mature in the bone marrow are termed B-2 cells. They are 
part of the adaptive immune response including the long-term T cell dependent 
antigen response and isotype switch and differentiate into high affinity memory B 
cells. Another phenotype of B cells is the B-1 cells. These cells are also part of the 
innate immune response and produce low affinity IgM antibodies that recognize 
bacterial antigen and self antigen (Porakishvili et al. 2001; Welner et al. 2008). B-1 cells 
develop from peritoneal precursor cells and are further divided into CD5 positive (+) 
B-1a cells and CD5 negative (-) B-1b cells. The CD5 molecule function is a regulator 
of BCR signaling by preventing incorrect activation of autoreactive B-1a cells 
(Bertland & Wortis 2002). Auto-antibodies produced by B-1a cells react to nuclear 
antigens, cell surface molecules and intracellular matrix proteins. This may, in turn, 
affect tolerance against self-antigens and lead to a dysfunction of the immune system 
(Klinman & Steinberg 1987). 
 
Large numbers of B-1a cells are found in peripheral blood from patients with 
autoimmune diseases, e.g. rheumatoid arthritis and Sjögren’s syndrome (Burastero et 
al. 1988; Youinou et al. 1988). Large amount of B-1a cells were also detected in lesions 
of chronic periodontitis patients. Subjects with periodontitis exhibit a larger fraction of 
circulating and local autoreactive B cells than periodontally healthy subjects 
(Berglundh et al. 2002; Sugawara et al. 1992; Aramaki et al. 1998). In a study by 
Berglundh and co-workers (1999) it was found that the amount of circulating B-1a 
cells did not decrease after successful non-surgical therapy in subjects with chronic 
periodontitis. It was suggested that the level of B-1a cells may be a marker for 
susceptibility rather than an indicator of the presence of disease.   
 
IL-10 
Interleukin (IL)-10 is a cytokine that is produced by many cells among which B cells 
and monocytes are the primary sources (Mocellin et al. 2004). The main cellular source 
of IL-10 may, however, vary in different tissues and also during acute and chronic 
stages of an infection (Couper et al. 2008). IL-10 is encoded by five exons on 
chromosome 1q31-32 (Eskdale et al. 1997; Mocellin et al. 2004; Mosser & Zhang 
2008). It was originally described as a cytokine mainly produced by Th2 cells and the 
function of which was to inhibit the production of pro-inflammatory cytokines (IL-1β, 
IL-6, IL-8, IL-12 and TNF-α) (Borish 1998; Fiorentino et al. 1989). IL-10 is also 
recognized as a pro-inflammatory cytokine that promotes a Th2 response as well as B 
cell proliferation and antibody production (Moore et al. 2001; Rousset et al. 1992). The 
main source of B cell-derived IL-10 is autoreactive B-1 cells. Auto-antigens and/or 
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bacterial antigens promote expression of IL-10, which may act as an autocrine growth 
factor for B-1 cells (O’Garra et al. 1992).  
 
While the anti-inflammatory function of IL-10 is considered important in the 
regulation of the inflammatory response  to microbial  infection (Moore et al. 2001), 
IL-10 may also contribute to the  development of  different diseases. High levels of 
IL-10 were found in patients with meningitis that had a poor or fatal outcome 
(Lehmann et al. 1995; Westendorp et al. 1997). Strong correlations were found between 
IL-10 plasma/tissue levels and chronic infectious diseases e.g. malaria, leprosy and 
AIDS (Mocellin et al. 2004). IL-10 can be either cancer-promoting due to its 
immunosuppressive features or cancer inhibiting through its anti-angiogenic 
characteristics (Howell & Rose-Zerilli 2007). B cells were found to produce high levels 
of IL-10 in several autoimmune diseases, e.g. Sjögren’s syndrome, rheumatoid arthritis 
and systemic lupus erythematosus (SLE) (Llorente et al. 1993; Llorente et al. 1994; 
Mongan et al. 1997). SLE is characterized by polyclonal B cell activation and high 
levels of serum auto-antibodies. Treatment with anti-IL-10 monoclonal antibodies 
resulted in a reduction of pathological conditions of the disease (Mocellin et al. 2004).  
 
The presence of IL-10 in periodontitis lesions was reported in several studies. Aramaki 
and co-workers (1998) found a larger amount of IL-10 in inflamed gingival tissue than 
in peripheral blood. Higher levels of IL-10 in periodontitis lesions than in gingivitis 
lesions were also demonstrated (Nakajima et al. 2005). In a study by Yamazaki and co-
workers (1997) the authors reported that the amount of IL-10 mRNA was higher in 
gingival tissues than in peripheral blood mononuclear cells in periodontitis patients. 
Stimulation of peripheral blood mononuclear cells with Porphyromonas gingivalis 
lipopolysaccharide (LPS) showed an association between high percentage of B-1a cells 
and high IL-10 production (Stein et al. 1997). These findings indicate that periodontal 
pathogens may induce an IL-10 response resulting in a proliferation of B-1a cells and a 
production of auto-antibodies. 
 
Genetic components 
Subjects with periodontitis exhibit a similar clinical phenotype but the biological 
mechanisms and factors resulting in this phenotype may differ between subjects. 
Periodontitis is a complex disease associated with variations in multiple genes. It has 
been estimated that 10 to 20 genes may contribute to the disease. The immune 
response to a pathogen is influenced by different factors, genetic as well as epigenetic 
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modifications were proposed to be key components in the expression of periodontitis 
(Loos et al. 2008; Offenbacher et al. 2008). 
 
Genetic modifications can occur in the DNA resulting in variations in the nucleotide 
sequence. The most common change in the genome is a single nucleotide base pair 
substitution called a single nucleotide polymorphism (SNP). This results in a shift in 
base pair from a G-C (guanine-cytosine) to an A-T (adenine-thymine) base pair. A part 
of a chromosome or several SNPs on a segment of a chromosome that are inherited 
together is called a haplotype (Snustad & Simmons 2010). SNPs are mostly located in 
coding regions of the gene resulting in a change in the amino acid sequence of the 
protein and, hence the function of the protein. If a SNP occurs in the promoter of a 
gene this may alter the binding of regulatory proteins to the DNA and thereby 
influencing gene transcription. Several gene polymorphisms in various genes have 
been studied to investigate their role in periodontitis, e.g. CD14, IL-1α, IL-1β, IL-4, 
IL-6, MMP 1,3 and 9, TLR2, TLR4 and also IL-10 (Loos et al. 2008). The association 
of the –1087 IL-10 single nucleotide polymorphism and periodontitis was studied in 
different populations (Berglundh et al. 2003; Scarel-Carminaga et al. 2004; Yamazaki et 
al. 2001). It was suggested that the -1087 IL-10 polymorphism in the IL-10 promoter 
was associated with severe chronic periodontitis in Caucasian subjects (Berglundh et al. 
2003). 
 
In summary, the expression of a gene is either regulated at the transcriptional level 
through influences by SNPs and haplotypes, or post-transcriptionally during the 
translation process of converting mRNA into protein. Furthermore, a second level of 
regulation is the chromatin status of the DNA. This process is termed epigenetic and 
is not encoded in the DNA. In the present series the focus was on the transcriptional 
regulation of B cell-derived IL-10 and the influence of epigenetic modifications of the 
chromatin in the IL-10 promoter region. The principles of these two mechanisms are 
described below. 
 
Transcriptional regulation 
Transcription is the process in which genetic information in the DNA is transferred to 
RNA (Snustad & Simmons 2010). Most of the regulation of genes occurs at the 
initiation of the transcription process. In protein coding genes the transcription is 
performed by RNA polymerase II (RNA pol II). There are two regulatory DNA 
elements: the promoter and distal regulatory elements, which can be either enhancers 
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or silencers. The core promoter is located upstream from the transcription start point 
and serves as the point of assembly for the basal transcriptional machinery and 
initiation of transcription (Maston et al. 2006; Snustad & Simmons 2010). 
  
Transcription factors are cellular components that bind to the DNA and regulate gene 
expression. Such factors can be expressed in either most tissues having a broad 
function or in one or two tissues indicating a specific function. Transcription factors 
influence the promoter in different ways depending on the stimuli or tissue type, and 
will induce a higher transcription activity compared to the basal transcription 
(Farnham 2009; Maston et al. 2006) (Fig 3).  
 
 
Fig 3. A model for transcriptional regulation. The RNA pol II and general transcription factors bind 
to the proximal promoter. Activators bind to distal enhancer elements and by protein-protein 
interactions with co-activators a bending of DNA (DNA looping) occurs (Vilar & Saiz 2005). 
Transcription factors binding to distal promoter regions may thereby influence the transcription 
machinery and regulate transcription. (Modified from Farnham 2009). 
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In the present thesis the transcription 
factors PU.1 (Spi-1), Spi-B and Sp1, and 
their roles in the regulation of IL-10 
were investigated. PU.1 and Spi-B are 
members of the ETS transcription 
factor family. They share a 43% overall 
amino acid sequence identity and a 67% 
identity in the DNA binding domain 
(Ray et al. 1992). The ETS transcription 
factors recognize and bind to DNA 
sequences containing the core motif 5’-
GGAA/T-3’. The sequence of 
nucleotides flanking this core motif is 
specific for the different members of 
the ETS family (Gallant & Gilkeson 
2006). PU.1 is expressed in B cells, mast 
cells, megakaryocytes, macrophages and 
neutrophils, while Spi-B is only present 
in the lymphoid lineage (Su et al. 1996). 
These transcription factors are essential 
in the regulation of the immune 
response and the lymphocytic 
development (Gallant & Gilkeson 2006; 
Su et al. 1996). PU.1 and Spi-B can bind 
to identical DNA-binding sequences 
and activate the same target genes in vitro (Ray et al. 1992; Su et al. 1996). Sp1 is a 
member of the Sp/XKLF (specificity protein /Krüppel-like factor) family of 
transcription factors (Fig 4). These transcription factors recognize and bind to GC-
(GGGGCGGGG) boxes. Sp1 regulates transcription through interactions with the 
basal transcriptional machinery by binding to the TATA-box binding protein (TBP) or 
by binding to distal enhancer regions (Bouwman & Philipsen 2002; Courey & Tjian 
1988; Emili et al. 1994). Sp1 is involved in cell cycle regulation, chromatin remodeling 
and maintenance of methylation free islands (Brandeis et al. 1994; Li et al. 2004; 
Macleod et al. 1994).  
 
Sp1 binding to several sites in a promoter is characterized by multiple Sp1 complexes 
through protein-protein interactions forming a loop between distally and proximally 
bound Sp1 molecules. This multimer complex interacts with other DNA binding 
proteins, transcriptional regulators and chromatin remodeling factors (Li et al. 2004; Su 
Fig 4. A 3D model of  the DNA binding domain 
of  Sp1 binding to DNA published by Marco et 
al (2003). Reprinted with the perimission from 
Elsevier Science Ltd, ! 2003. 
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et al. 1991). Sp1 has also been shown to influence the gene expression through binding 
to ETS transcription factors (Dittmer et al. 1997; Lu et al. 2006) and by interaction with 
the p65 subunit of NFκB. The p65-Sp1 complex recruits TBP associated factors and 
polymerase II that results in an increase in gene expression (Perkins et al. 1994). 
 
Epigenetic modifications 
The term epigenetics relates to mitotic and/or meiotic inherited changes in gene 
expression that are not encoded in the DNA sequence itself (Bird 2002). Epigenetic 
modifications include chemical alterations of the DNA and its associated proteins. 
Such alterations lead to remodeling of the chromatin and activation or inactivation of 
a gene. DNA methylation and histone acetylation and methylation are the major 
epigenetic modifications. They occur and 
contribute to the development of cancer, 
autoimmune and inflammatory diseases. 
Epigenetic alterations of a gene can be 
induced by environmental factors (Gomez 
et al. 2009; Wilson 2008). 
  
DNA is stored in the nucleus as a 
chromatin complex (Fig 5).  Nucleosomes, 
which are the basal structure components 
of chromatin, consist of 146 bp DNA and 
a core histone complex including two 
copies each of histone H2A, H2B, H3 and 
H4 and the linker histone H1 that connects 
the nucleosomes (Fitzpatrick & Wilson 
2003; Workman & Kingston 1998).  
 
Histone acetylation is regulated by histone 
acetyltransferases (HATs) and histone 
deacetylases (HDACs). Histone 
deacetylases remove acetyl groups, which 
lead to alterations in the packing of DNA 
around histones (Bäckdahl et al. 2009). 
Hyperacetylation is associated with 
Fig 5. The organisation of  DNA within the 
chromatin structure. Adapted from Qiu 2006. 
Reprinted with permisson from Macmillan 
Publishers Ltd: Nature, © 2006. 
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transcriptional active chromatin, while hypoacetylation is associated with inactivated 
regions of the chromatin (Jenuwein & Allis 2001; Turner 2000).  
  
Methylation occurs at different lysine molecules on histones H3 and H4, and is 
important in the formation of the chromatin. The complex mechanism of this process 
is currently a main research area with focus on evaluating the influence of the different 
possible lysine methylation patterns.  Histone lysine methylation can result in both 
active and inactive chromatin depending on the type of lysine molecule (Martin & 
Zhang 2005). Furthermore, certain lysine molecules can be mono-, di- or trimethylated 
(Farnham 2009; Green et al. 2006; Pinskaya & Morillon 2009). Recent studies indicate 
that certain transcription factors have affinity for specific histone modifications and 
that the combination of transcription factors and co-activators are responsible for the 
specific histone code that is associated with certain genes. The resulting combinations 
of histone modifications may promote unique cellular responses (Jenuwein & Allis 
2001; Turner 2000).  
 
The DNA itself can be modified by the addition of methyl groups to a cytosine 
situated next to a guanine, so called CpG islands or CpG sites. Such sequences are 
associated with promoter regions but also 5’ ends of many genes (Bird 2002; 
Robertson & Wolffe 2000). Methylation of the DNA results in silencing or down- 
regulation of a gene, whereas transcriptionally active genes are associated with low 
levels of DNA methylation. DNA methylation inhibits gene expression either by 
inhibiting the binding of transcription factors, or by recruitment and binding of 
regulatory proteins that contains a methyl-CpG binding domain to the DNA. These 
proteins assemble a complex containing co-repressors and histone deacetylases, which 
make the chromatin inaccessible for transcription factor binding (Fitzpatric & Wilson 
2003). While acetylation of histones is a transient mechanism, methylation of the 
DNA is stable and can sustain through cell division (Bäckdahl et al. 2009). It has been 
suggested that DNA methylation and histone modifications are linked (Robertson & 
Wolffe 2000) (Fig 6).  
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Fig 6. The mechanism for gene silencing by DNA methylation and histone deacetylation. A 
transcriptional active region is characterized by histone acetylation and an open chromatin structure. 
Methylation of the cytosine molecules in the DNA results in the recruitment of methyl-CpG-binding 
proteins and histone deacetylases. The deacetylated chromatin forms a tightly packed structure that 
inhibits the binding of transcription factors. (Adapted from Robertson & Wolffe 2000). 
 
 
In a recent review by Bäckdahl et al. (2009) the authors suggested that hypo-acetylated 
histones and hyper-methylated CpGs in chronic inflammatory diseases may result in 
persistent inflammation. DNA methylation may also be promoted by chronic 
inflammation and bacterial infection (Bobetsi et al. 2007). Epigenetic modifications of 
a certain part of a gene can differ between cell types and may result in a different local 
and systemic expression of a gene. Research on epigenetic modifications in 
combination with genetic analysis may provide further evidence to inter-individual 
differences in local expression of genes associated with inflammation. 
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Transcriptional and epigenetic regulation of IL-10 gene expression 
About 75% of the IL-10 production in blood cells following LPS-stimulation is 
determined by genetic factors (Westendorp et al. 1997). The inter-individual genetic 
variability in IL-10 production was suggested to be a result of differences in the 
transcriptional regulation and the activity of the promoter for IL-10 (Rees et al. 2002). 
The IL-10 gene promoter was sequenced in 1995 by Kube and co-workers in EBV-
positive Burkitt’s lymphoma cells (Kube et al. 1995). Several regulatory regions has 
then been identified in the 5’ flanking region, including two dinucleotide repeats 
(microsatellites) located 1.2 kb (IL10.G) and 4 kb (IL10.R) upstream of the 
transcription start site. A positive regulatory sequence was identified in the promoter 
region between –1100/-800 (Eskdale et al. 1995,1996,1997; Kube et al. 1995). Three 
linked single nucleotide polymorphism (SNP) are present in the IL-10 promoter; -1087 
(G/A), -824 (C/T) and -597 (C/A) which together form the haplotypes ATA, ACC 
and GCC associated with low, medium and high levels of IL-10 production 
(Hoffmann et al. 2001). Eskdale et al. (1999) combined the microsatellites and the 
haplotypes for the three SNPs and investigated the distribution of the alleles. Four 
core haplotype families were constructed: 
IL10.01: R3-(IL10.G).G-C-C 
IL10.02: R2-(IL10.G)-A-C-C 
IL10.03: R2-(IL10.G)-G-C-C 
IL10.04: R2-(IL10.G)-A-T-A 
The results showed a higher IL-10 protein expression for the IL10.02 haplotype than 
the IL10.03 haplotype when the IL10.G allele 13 was present. Haplotypes containing 
the IL10.R3 allele were found to produce lower amounts of IL-10 than IL10.R3 
negative alleles (Eskdale et al. 1998). 
 
The –1087 G/A SNP (sometimes referred to as -1082) was associated with differences 
in IL-10 promoter activity and IL-10  production. The results on  the influence of the 
–1087 SNP on the IL-10 production in different cell types are, however, conflicting. 
Thus, the presence of an A was shown to result in an increase in the IL-10 promoter 
activity (Rees et al. 2002). Conversely, other reports have suggested that the G-allele of 
–1087 was associated with an increase in the IL-10 promoter activity (Crawley et al. 
1999; Kremer et al. 2007; Reuss et al. 2002, Turner et al. 1997). The -1087 SNP was also 
associated with different diseases, e.g. joint destruction (Huizinga et al. 2000), 
susceptibility to EBV infection (Helminen et al. 1999), inflammatory bowl diseases and 
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Ulcerative colitis (Tagore et al. 1999). A correlation between IL-10 haplotypes and 
progression of periodontitis was reported. Haplotypes negative for the -1087 G-allele 
experienced 20% fewer sites with probing depth of ≥4 mm during a 5-year period 
(Cullinan et al. 2008). 
 
The –1087 SNP lies in a GGAA/G motif and the transcription factor PU.1 was found 
to bind to the –1087 site in a human monocytic cell line (Reuss et al. 2002). 
Recognition sequences for a number of other transcription factors have also been 
identified in the IL-10 promoter, including AP1, Sp1 (Kube et al. 1995), cMaf (Cao et 
al. 2005), C/EBP (Liu et al. 2003) and Stat (Staples et al. 2007). Although all these 
transcription factors influence IL-10 gene expression, Sp1 in particular was found to 
be an important factor in IL-10 gene expression. The Sp1 binding site at -89 to -77 bp 
is essential for IL-10 promoter activity in T cells and macrophages in both humans 
and mice (Brightbill et al. 2000; Tone et al. 2000). An additional Sp1 binding site has 
been located upstream of the -571 site (Steinke et al. 2004). 
 
The transcriptional regulation of IL-10 is complex and the chromatin may be 
differently modified in different cell types. Several studies on the regulation on IL-10 
gene expression emphasize the important role of Sp1 in the transcription of IL-10, 
and different mechanisms for this activation have been proposed. Sp1 induced IL-10 
transcription is activated by LPS binding to the LPS binding protein (LBP) and this 
complex interacts with the CD14 receptor on the cell surface. CD14 then transfers 
LPS to the transmembrane signaling receptor Toll-like receptor 4 (TLR4) and its 
associated receptor myeloid differentiation-2 protein (MD2) (Miyake 2004). This 
process activates signaling through three MAPK pathways (ERK, JNK and p38), 
which in turn activates and up-regulate nuclear translocation of Sp1 (Chanteux et al. 
2007). Inhibition of ERK activation prevents histone modifications and decreases Sp1 
binding to the IL-10 promoter. Activation of ERK results in transient modifications in 
the chromatin at the IL-10 locus, which make the IL-10 promoter accessible to 
transcription factors leading to an increase in IL-10 expression (Zhang et al. 2006).  
 
Additional mechanisms for Sp1 induced IL-10 production have been reported. The 
transcription factor NFκB regulates the expression of several genes involved in 
inflammatory processes. An interaction between NFκB and Sp1 has been shown to 
result in an increase in promoter activity. However, a report on NFκB and IL-10 
transcription suggested that Sp1 may be the key regulator of IL-10 expression and that 
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NFκB is not necessary for the IL-10 expression (Brightbill et al. 2000). IL-10 
transcription can also be induced by the human immunodeficiency virus (HIV) trans-
activator (Tat) protein. The IL-10 promoter contains a Tat-responsive sequence 
located at -625 to -610. Ets1 and Sp1 have been identified to bind to this sequence and 
to be activated by p38 (Li & Lau 2007). Chiang and co-workers (2006) used mouse 
macrophage cells and showed that Sp1 interacts with C/EBPδ after LPS-stimulation 
and thereby co-activates IL-10 gene expression. Two models for the complex 
formation and gene activation were presented. The first model suggested that the 
C/EBPδ-Sp1 complex is formed in the nucleus and binds to the IL-10 promoter. An 
alternative model was that Sp1 binds to the recognition site in the promoter and then 
C/EBPδ binds to the Sp1.  
 
In addition to different transcription factors participating in and influencing the 
transcriptional regulation of IL-10 described above, DNA methylation of CpG sites in 
the IL-10 promoter may also regulate gene transcription. However, tissue specific 
genes such as IL-10 have low numbers of CpG sites. In the IL-10 promoter there are 
8 CpG sites in the proximal 700 bp promoter region (Szalmás et al. 2008; Tsuji-
Takayama et al. 2008). Research on the methylation pattern showed differences 
between IL-10 producing cells and IL-10 non-producing cells in methylation of the 
two proximal CpG sites at positions -185 and -110 in the promoter (Szalmás et al. 
2008). Treatment with 5-aza, an inhibitor of DNA methyltransferases, resulted in an 
increase in IL-10 production. This indicates that the IL-10 gene expression can be 
regulated by DNA methylation (Dong et al. 2007). 
 
Histone modifications near the IL-10 promoter region are associated with IL-10 gene 
silencing. The transcriptional active promoter in an IL-10 producing cell exhibits an 
open chromatin configuration and a high degree of acetylated histone H3 and histone 
H4 in the proximal part of the promoter. IL-10 producing Th cells were found to be 
hyperacetylated on histone H4 even prior to stimulation. Such cells showed a basally 
low expression of IL-10 and a rapid induce of IL-10 mRNA after stimulation (Im et al. 
2004). 
 
Even though several studies on epigenetic modifications of IL-10 promoter indicate 
the importance of the epigenetic status of the proximal part, there are reports 
suggesting that HDAC proteins in the distal part may induce changes in the three 
dimensional chromatin structure resulting in a bending of the distal region towards the 
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proximal region (Villagra et al. 2009). Regulatory factors bound to the distal part of the 
promoter could thereby regulate the proximal region, through changes in histone 
acetylation and transcription factor binding needed for the activation of IL-10. 
 
Sp1 is known to affect DNA methylation but data on the influence of methylation on 
Sp1 binding are conflicting. DNA methylation of a CpG site in an Sp1 recognition 
sequence does not interfere with binding of Sp1. It was suggested that Sp1 prevents 
methylation and is important in keeping CpG sites unmethylated. However, 
methylation of the cytosine outside or nearby CpG sites inhibits Sp1 binding (Clark et 
al. 1997; Zhu et al. 2003). The absence of methylation at methylation-free islands in 
housekeeping genes was suggested to be a consequence of the constitutive binding of 
Sp1 at these sites (Höller et al. 1988). In the study referred to, the results showed that 
Sp1 can bind to both methylated and unmethylated sites, and that CpG methylation at 
these sites does not inhibit transcription.  
 
The regulation of IL-10 is a key mechanism in keeping the immune balance in vivo. 
Even though a lot of research has been performed on the different regulatory 
mechanisms of IL-10 gene expression, the regulation of IL-10 is still poorly 
understood. The -1087 SNP is associated with high IL-10 production and has also 
been associated with disease. However, limited information on the function of this 
SNP in the regulation of IL-10, and in particular in B cells, is available. We thus, 
analyzed the binding pattern of transcription factors to this site in the IL-10 promoter 
(study I and II). We also investigated the result of an alteration in binding pattern to 
this site on the promoter activity and gene expression (study I and II). The 
identification of transcription factor Sp1 binding to -1087 and the correlation between 
IL-10 and Sp1 mRNA transcription prompted the analysis of Sp1 in periodontitis 
lesions (study III). The presence of transcription factors in most cell types and the 
tissue specific expression of the IL-10 gene suggested a second level of regulation, i.e. 
epigenetic modifications of the DNA and histones (study IV). 
  
In conclusion, the transcriptional regulation of IL-10 is complex and may be 
influenced by both genetic and epigenetic factors. Research on the regulation of IL-10 
suggests specific mechanisms related to cell type and stimuli. Different transcription 
factors and signaling pathways are most probably involved in the IL-10 gene 
expression with Sp1 as a key factor (Fig 7). The association of the high IL-10 
producing -1087 GG genotype and periodontitis indicates a possible difference in the 
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IL-10 promoter regulation between subjects. These differences may be genetic and/or 
epigenetic. Therefore, research on genetic and epigenetic modifications may provide 
new information on pathological processes and suggest new treatment models, not 
only for periodontitis but also for other diseases characterized by a chronic 
inflammation. 
 
Fig 7. A model of the different Sp1 signaling pathways involved in the regulation of IL-10 gene 
expression. 
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Aims 
 
Overall aim 
IL-10 is an important cytokine in the regulation of the inflammatory response in a 
number of diseases. The variation in IL-10 production between subjects is genetically 
determined and the regulation of IL-10 is predominantly on the transcriptional level. 
The IL-10 promoter contains a number of regulatory elements and the -1087 single 
nucleotide polymorphism is found to be important for IL-10 gene expression. 
However, there is limited knowledge on the function of this SNP. The overall aim of 
the present series of studies was to examine functional aspects of the -1087 IL-10 
gene polymorphism. 
 
 
Specific aims: 
• To analyze differences in transcription factor binding to the -1087 position in the 
IL-10 promoter region in B cells. 
 
• To study  the influence  of the  -1087 A/G  nucleotide transition on IL-10 and Sp1 
gene expression. 
 
• To analyze differences  in  Sp1  expression in  periodontitis  lesions in GG and AA 
genotype subjects. 
 
• To study epigenetic  modifications around the -1087 site  and their influence on 
IL-10 gene expression  
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Material and methods 
 
Study population (study II, III and IV) 
The study protocols were approved by the local human review board and prior to 
enrollment all subjects received information about the study and signed an informed 
consent. In study II periodontally healthy subjects were recruited. The subjects 
demonstrated normal radiographic bone levels, i.e. a distance of <3 mm between the 
cemento-enamel junction (CEJ) and the most coronal level of bone crest (BC) at 
>95% of the proximal tooth sites. In study III and IV subjects with severe, 
generalized chronic periodontitis were recruited at the Clinic of periodontics, 
Gothenburg.  
 
Genotyping (study II, III and IV) 
In study II, III and IV blood samples were collected from subjects with severe, 
generalized chronic periodontitis and from periodontally healthy subjects. Genotyping 
was performed to  identify subjects with either GG or AA genotypes for the -1087 
IL-10 gene polymorphism. DNA was extracted and genotyped for the -1087 IL-10 
gene polymorphism rs1800896 (Berglundh et al. 2003; Padyukov et al. 2001). 
 
Cell lines (study I, II and IV) 
The cell lines used in these studies were the Schneider’s Drosophila line 2 (SL2) (study 
I), the DG75 B cell line (study I) and B cell lines from subjects with either GG or AA 
genotypes (study II and IV). SL2 is a Drosophila cell line that does not express the Sp1 
transcription factor endogenously (Courey & Tjian 1988). The SL2 cells were grown 
at 28°C in Schneider’s Drosophila medium supplemented with 10% fetal bovine serum, 
100 U penicillin ml-1 and 100 µg streptomycin ml-1. DG75 is an Epstein Barr (EBV)-
negative Burkitt’s lymphoma B cell line (Ben-Bassat et al. 1977). In order to study the 
influence of the -1087 gene polymorphism on IL-10 gene expression B cell lines were 
established from subjects with GG and AA genotypes for the -1087 IL-10 gene 
polymorphism. Blood samples were collected and leukocytes were separated using 
density gradient centrifugation. Immortalization of the cells was done by infecting the 
B cells with the B95-8 strain of the EBV. The B cell lines were maintained as 
suspension cultures in RPMI-1640 medium supplemented with 10% fetal bovine 
serum, 100 U penicillin ml-1, and 100 µg streptomycin ml-1. The B cell lines were 
grown at 37°C in a humidified atmosphere containing 5% CO2. 
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Isolation of B cells (study II and IV) 
B cells were purified from peripheral blood samples collected from subjects with GG 
and AA genotypes for the -1087 IL-10 gene polymorphism using the MACS magnetic 
cell sorting technique and anti-CD19 microbeads (Miltenyi Biotech GmbH, Bergisch 
Gladbach, Germany) (study II and IV). The purity of the B cells was about 96% as 
confirmed by FACS. The B cells were grown in RPMI-1640 medium supplemented 
with 10% fetal bovine serum, 100 U penicillin ml-1 and 100 µg streptomycin ml-1 at 
37°C in a humidified atmosphere containing 5% CO2. 
 
Tissue samples (study III and IV) 
In study III and IV gingival biopsies were obtained from subjects with severe, 
generalized chronic periodontitis and with either the GG or the AA genotype. The 
gingival biopsies were collected from diseased sites demonstrating bone loss ≥50%, 
probing pocket depth ≥6 mm and bleeding on probing. The biopsies were fixed in 4% 
formalin for minimum 24h, dehydrated and embedded in paraffin. In study III five-
micrometer sections  were  cut at a  microtome, dried at  37°C for 24 h and stored  at 
-70°C. In study III additional sections were obtained for RNA extraction, while in 
study IV sections were obtained for DNA extraction. 
 
Electrophoretic Mobility Shift Assay (study I) 
The Electrophoretic Mobility Shift Assay (EMSA) is a sensitive method for studying 
interactions between proteins and DNA (Garner & Revzin 1981). The protein-DNA 
binding reaction was performed in vitro by mixing nuclear extract with a labeled 
double stranded DNA probe. In study I double stranded synthetic 32P-labeled 
oligonucleotides corresponding to the sequence from -1099 to -1074 of the IL-10 
promoter, with either G or A at the -1087 position and nuclear extracts from DG75 
cells were used. The protein-DNA complexes were separated from free DNA by non-
denaturing polyacrylamide gel electrophoresis (PAGE), based on differences in 
charge, conformation and size. When a protein bound to the DNA it caused the 
complex to move slower and this resulted in a shifted band on the electrophoresis gel. 
To identify the proteins binding to the DNA, antibodies recognizing the target 
proteins were added to the reaction. When the antibody bound to the protein the size 
of the complex changed and resulted in a so-called supershift. To further verify the 
specificity of a band competition experiments were performed. In these experiments 
an excess of unlabelled probe was added to the reaction, band that disappeared were 
considered specific complexes shifted by target proteins.  
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The antibodies for the supershift experiments were Sp1 (sc-59 X), PU.1 (sc-352 X) 
and Spi-B (sc-5944 X) (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). In 
addition to unlabeled oligonucleotides corresponding to the sequence in the IL-10 
promoter consensus oligonucleotides for Sp1, ETS and C/EBP were also used. 
 
Transfection assays (study I) 
Two different methods for transient transfections were used in study I. Transient 
transfections of DG75 cells were performed using electroporation, while the SL2 cells 
were transfected using the Lipofectamine TM LTX kit (Invitrogen Corp, Carlsbad, CA, 
USA). The –1111 bp to +1 bp sequence of the human IL-10 promoter was fused into 
a plasmid in front of a luciferase reporter gene (Kremer et al. 2007). The two reporter 
plasmids were referred  to as  ACC and GCC  as defined by the G or A  nucleotide at 
–1082, C at –819 and C at the –592 position. The cells were transfected with the 
reporter plasmids and assayed for luciferase activity using the Luciferase Assay 
System. In addition, the SL2 cells were co-transfected with the reporter plasmids 
together with an Sp1 expression vector. The result of the assay was an indirect 
measurement of the promoter activity. 
 
Chromatin Immunoprecipitation Assay (study II and IV) 
In study II the Fast chromatin immunoprecipitation (ChIP) assay was done according 
to methods modified from those described by Nelson et al. (2006). EBV-
immortalized B cells were incubated for 24h with or without LPS. The cells were 
crosslinked by adding 37% formaldehyde and incubated for 7 minutes at room 
temperature, followed by the addition of glycine to stop the reaction. The cells were 
lysed in 100 µl/106 cells buffer A on ice (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 
mM KCl, 1 mM DTT, supplemented with proteinas inhibitors). After 10 minutes 
incubation, the nuclei were recovered by centrifugation. Chromatin was extracted in 
100 µl SDS lysis buffer per 2 x 106 cells for 10 minutes on ice (1% Triton X-100, 
0.1% SDS, 10 mM EDTA, 50 mM Tris pH 8.0, supplemented with protease 
inhibitors). The DNA was sonicated on ice into fragments of 500 to 1000 bp in size. 
The sheared chromatin was incubated with antibodies over night at 4°C. The 
antibodies used for ChIP were Sp1 (sc-14047 X), PU.1 (sc-352) and Spi-B (sc-5944) 
(Santa Cruz Biotechnology Inc.). A rabbit IgG antibody was used as a negative 
control and an anti-acetylated histone H3 antibody was used as a positive control 
(Millipore SAS, Molsheim, France). The immunocomplexes were captured using 
Protein A sepharose 4 fast flow, washed and precipitated. DNA fragments were 
isolated using 10% Chelex-100.  
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In study IV we used the ChIP-IT express enzymatic shearing kit and protein G-
coated magnetic beads (Active Motif, Carlsbad, CA, USA) to examine histone 
modifications of the IL-10 promoter region around the -1087 site. The antibodies 
used in this study were anti-acetyl-histone H3 (06-599), anti-acetyl-histone H4 (06-
866) and anti-mono/di/trimethyl-histone H3 lys4 (04-791) antibodies (Millipore 
S.A.S, Molsheim, F).  
 
RNA analysis and real-time PCR (study II, III and IV) 
To study the IL-10 and Sp1 gene expression, RNA was extracted from cells (study II 
and IV) or gingival tissues (study III), converted into cDNA and analyzed using real-
time PCR. The relative gene expression of IL-10 and Sp1 were calculated by 
normalizing the Ct values of the target genes to the Ct values of two or three 
reference genes according to the 2-ΔΔCT method (Livak & Schmittgen 2001; Pfaffl 
2001). For stability comparisons of suitable reference genes the software geNorm 
(Vandesompele et al. 2002) was used. In addition, the software NormFinder 
(Andersen et al. 2004) was used in study II.  
 
ELISA (study II) 
Enzyme-linked immunosorbent assay (ELISA) is a method for detection and 
quantification of antibodies or antigens. In study II the concentration of IL-10 protein 
were assayed using the IL-10 human Easy ELISA kit (GE Healthcare Bio-sciences 
AB, Uppsala, Sweden). The supernatant from the cell cultures was added to a 96-well 
plate coated with anti-IL-10 antibodies. Following incubation with a detection 
antibody and a subsequent addition of a streptavidin-HRP complex, a substrate 
reactive with HRP was added to the reaction. This resulted in a colored product, 
which was formed in proportion to the amount of IL-10 present in the sample. The 
absorbance was measured in a spectrophotometer at 450 nm. 
 
RNA interference (study II) 
RNA interference (RNAi) is a process where single-stranded RNA molecules bind to 
mRNA in a sequence–specific manner, resulting in RNA degradation and gene 
silencing. A double-stranded RNA called a short interfering RNA (siRNA) is 
introduced into the cell and enters the RNAi pathway of the cell. In study II the 
influence of Sp1 knockdown on IL-10 gene expression was analyzed by transfecting 
Sp1 siRNA into B cell lines from subjects with either GG or AA genotypes. The Sp1 
siRNA and the pEGFP-C3 expression vector were transfected into the cells using 
electroporation. In some experiments, LPS was added to the cells 48h after the 
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electroporation. After 72h the cells were harvested and RNA was extracted. The 
decrease in IL-10 mRNA was measured and compared to the IL-10 mRNA 
transcription in cells transfected with a negative control siRNA. 
 
in situ Proximity Ligation Assay (study III) 
in situ Proximity Ligation Assay (in situ PLA) was used in study III for detection and 
quantification of Sp1 positive cells in periodontitis lesions. The in situ PLA was done 
using an Sp1 primary antibody (sc-420 Santa Cruz Biotechnology Inc.), the Duolink 
single recognition system and the Nova Red detection system (OlinkBioscience, 
Uppsala, Sweden). Briefly, after incubation with the primary antibody, the two 
secondary PLA probes conjugated to antibodies were added and the oligos hybridized 
and ligated to form circular DNA strands. Signal amplification was done by 
replicating the DNA circles via rolling circle amplification (RCA) using DNA 
polymerase (Jarvius et al. 2007). After amplification detection was performed using a 
complementary HRP-labeled probe. Quantification of the Sp1 positive cells and Sp1 
protein molecules was made using the BlobFinder software (Allalou & Wählby 2009). 
 
Immunohistochemistry (study III) 
A double immunohistochemistry (IHC) staining protocol for detection of Sp1 
positive B cells were used in study III. CD20-positive B cells were detected using the 
MACH2 alkaline phosphatase system and the Vulcan Fast Red substrate (Biocare 
Medical, Concord, CA, USA). Sp1 positive cells were visualized by a second 
incubation with the MACH2 system and the Ferengi Blue substrate (Biocare Medical). 
The antibodies used were CD20 (M0755 DakoCytomation A/S, Glostrup, DK) and 
Sp1 (sc-420 Santa Cruz Biotechnology Inc.). The density of labeled cells was assessed 
using a point counting procedure. A lattice comprising 400 points was superimposed 
over the tissue area. Cross points that indicated the positive cell markers in the 
compartment to be examined were counted and related to the total counts for the 
entire inflammatory cell infiltrate. 
 
Analysis of epigenetic modifications (study IV) 
To analyze the influence of DNA methylation on the IL-10 promoter B cells were 
treated with 5-aza. This drug induces DNA de-methylation, which may reactivate 
silenced genes and increase gene transcription. The cells were incubated with 5-aza for 
72h. Histones in transcriptionally silent regions are usually deacetylated. Treatment 
with Histone deacetylase inhibitors (HDACi) changes the conformation of the 
nucleosome and thereby activates the gene transcription. In order to study the 
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influence of histone modifications on the IL-10 gene transcription, B cells were 
treated with the HDAC inhibitors TSA, VPA or Butyrate for 48h. The IL-10 mRNA 
expression after treatment with these substances were measured and compared to un-
treated cells. 
 
Bisulfite modification analysis (study IV) 
Methylated cytosines cannot be detected using conventional sequencing. Thus, in 
study IV the sodium-bisulfite DNA modification technique (Herman et al. 1996) was 
used. DNA from peripheral blood was treated with sodium bisulfite, which converted 
all unmethylated cytosines into uracils. This modified DNA was then amplified using 
PCR and the methylation pattern of the three CpGs distal of the -1087 SNP was 
analyzed using DNA sequencing modified from those described by Sanger (Sanger 
1977). The components were DNA, heat resistant DNA polymerase, 4 dNTPs, 4 
ddNTP’s (dideoxy terminator nucleotides) fluorescently labeled with four different 
dyes and buffer containing MG2+ and K+. The primer bound to the complementary 
DNA strand and was extended in a linear mode until a ddNTP was incorporated. The 
dideoxy-configuration prevented the polymerase from adding any other base to the 
fragment and the extension was terminated. Thus, at the end of the cycles numerous 
fragments with different lengths and one labeled nucleotide were generated. After 
post sequencing reaction cleanup, the samples were sequenced and the fluorescent 
signal translated into a nucleotide sequence. The sequencing analysis was performed 
at Eurofins MWG Operon (Ebersberg, Germany)  
 
In addition, DNA from blood and tissue samples was analyzed using High resolution 
melt curve analysis (HRM) and acrylamide electrophoresis. In the HRM analysis a 
HRM melting curve was performed after the PCR amplification. The unmethylated 
and methylated controls have different contents of methylcytosine, which resulted in 
different melting temperatures and thereby different HRM melting curves. The 
melting curves of the DNA samples were then compared to those of the controls. For 
the acrylamide electrophoresis PCR amplicons were incubated with the restriction 
enzyme Hph1 and the fragments were separated on a 20% acrylamide gel. 
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Data analysis (study I, II and III) 
In study I differences in luciferase reporter activity were analyzed using analysis of 
variance (ANOVA), the Student’s t-test and the Student-Newman-Keuls test. In study 
II differences in IL-10 mRNA transcription and IL-10 protein production were 
analyzed using the Mann-Whitney test. The two sample non-parametric Wilcoxon test 
was used in study III for evaluation of differences in Sp1 and IL-10 mRNA 
expression, as well as differences  in cell  densities of Sp1  positive cells, Sp1 positive 
B cells and Sp1 protein molecules. In all studies p-values <0.05 were considered 
significant. 
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Results 
 
Binding of transcription factors to the -1087 position in the IL-10 promoter (study 
I and II) 
The EMSA analysis performed in study I resulted in three specific complexes using 
the 1087G probe and two specific complexes using the 1087A probe. It was 
demonstrated that PU.1 and Spi-B bound to the region around -1087 in both the G-
and the A-allele. The transcription factor Sp1, however, only bound when there was a 
G at -1087. A 4th complex was identified for both probes and the results indicated 
that it was ETS related. In study II chromatin immunoprecipitation assay was used to 
investigate differences in binding of PU.1, Spi-B and Sp1 to the -1087 position in the 
in vivo situation in B cell lines from subjects with GG or AA genotypes. The analysis 
revealed a larger increase of PU.1 and Spi-B for the GG genotype (IgG fold 7.5 and 
4.7 respectively) than for the AA genotype (1.8 and 0.5). These differences were 
statistically significant (PU.1; p=0.034, Spi-B; p=0.046). The corresponding results for 
the transcription factor Sp1 were 6.0 for GG genotype cells and 0 for the AA 
genotype cells (p=0.028). 
 
Influence of the -1087 IL-10 gene polymorphism on IL-10 gene expression (study 
I and II) 
We evaluated the relation between the IL-10 promoter function and the presence of 
A or G at -1087 using transient transfection. DG75 B cells were transfected with 
reporter constructs with G or A at -1087. After 24h of LPS-stimulation cells 
transfected with the GCC reporter plasmid showed a 15-fold increase in promoter 
activity, whereas the untreated cells showed a 5-fold increase. For the cells transfected 
with the ACC reporter plasmid, the fold increase was sixfold for the stimulated cells 
and threefold for the un-stimulated cells. Moreover, co-transfection of SL2 cells with 
increasing amount of an Sp1 reporter plasmid resulted in a corresponding increase in 
promoter activity. Transfection with 0.5 µg of Sp1 expression vector resulted in a 
fourfold activation for the GCC reporter plasmid, whereas transfection with 1µg of 
Sp1 vector resulted in 10-fold increase in promoter activity. For the ACC reporter 
plasmid, the corresponding fold activation was two and four, respectively. This 
difference was statistically significant when using 1 µg of Sp1 expression vector 
(p=0.0043) (study I).  
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In study II, we also analyzed the IL-10 gene expression by measuring the amount of 
IL-10 and Sp1 mRNA in B cells from subjects with either AA or GG genotypes. 
Following LPS-stimulation GG genotype cells exhibited a larger increase in both IL-
10 and Sp1 mRNA transcription (1.6 and 1.2 fold, respectively) than AA genotype 
cells (1.0 and 0.8). The difference in Sp1 mRNA expression was statistically significant 
(p=0.041). LPS-stimulation of purified B cells revealed a larger fold increase in IL-10 
mRNA for the GG genotype cells than for the AA genotype cells (3.3 and 1.0, 
respectively). The corresponding increase in Sp1 mRNA transcription was 1.8 for the 
GG and 1.2 for the AA genotype cells.  
 
In order to investigate whether the increase in IL-10 mRNA expression after LPS-
stimulation resulted in a corresponding increase in IL-10 protein production we 
analyzed the supernatants from the cell cultures using the ELISA technique. The 
analysis showed that LPS treatment of GG genotype cells resulted in a concentration 
of 125 pg/ml of IL-10 compared to 85 pg/ml for the AA genotype cells. The 
corresponding numbers for the untreated cells were 81 vs. 59 pg/ml. For the purified 
B cells LPS-stimulation resulted in 173 pg/ml for the GG genotype and 12 pg/ml for 
the AA genotype cells. Untreated purified B cells from GG genotype subject had a 
131 pg/ml IL-10 production compared to 12 pg/ml for the AA genotype cells. 
 
The significance of Sp1 on IL-10 gene expression was further studied using RNA 
interference. These experiments resulted in a decrease in both Sp1 and IL-10 mRNA 
for cells transfected with an Sp1 siRNA in relation to cells transfected with the 
control siRNA. In LPS-stimulated GG genotype cells the reduction in Sp1 mRNA 
was 40%±23% in the LPS-stimulated cells and 36%± 9% in the un-stimulated cells. 
The corresponding numbers for the AA genotype were 37%±13% in the LPS 
stimulated and 41%±29% in the un-stimulated cells. The remaining IL-10 expression 
after transfection with Sp1 siRNAs was in the LPS-stimulated B cells 58% for the GG 
genotype and 72% for the AA genotype. In non-stimulated cells the remaining IL-10 
expression was 66% for the GG genotype and 77% for the AA genotype. 
 
Expression of Sp1 in the periodontitis lesion (study III) 
The results in study II showed a larger Sp1 mRNA expression in GG genotype cells 
compared to AA genotype cells. Thus, we evaluated the possibility of differences in 
Sp1 expression in periodontitis lesions from subjects with either GG or AA 
genotypes (study III). 25 subjects  with chronic  periodontitis  were genotyped  for the 
-1087 IL-10 gene polymorphism. Among these subjects 32% were GG, 40% were 
AG and 28% were AA genotypes. Quantification of Sp1 mRNA in the periodontitis 
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lesions revealed a 4-fold increase in Sp1 mRNA in GG genotype subjects compared 
to AA genotype subjects. The GG genotype subjects also had a 4 fold increase of IL-
10 mRNA in the lesion compared to the AA genotype subjects. In periodontitis 
lesions from GG genotype subjects 64% (SD 13%) of the cells were Sp1 positive 
compared to 35% (SD19%) for the AA genotype subjects (p<0.005). Using double-
staining immunohistochemistry it was shown that 79% (SD17%) of the B cells in 
periodontitis lesions from subjects with the GG genotype were Sp1 positive while in 
subjects with the AA genotype 61% (SD 26%) of the B cells were Sp1 positive. This 
difference was statistically significant (p=0.05). Moreover, there was a larger number 
of Sp1 protein molecules in periodontitis lesions from subjects with the GG genotype 
(2679, SD 1211 RCPs) compared to subjects with the AA genotype (1687, SD 781 
RCPs).  
 
Influence of epigenetic modifications on the IL-10 gene expression (study IV) 
Gene expression is not only regulated by genetic factors but is also influenced by 
epigenetic modifications of the chromatin. We therefore investigated the influence of 
histone modifications and DNA methylation on B cell-derived IL-10 transcription 
(study IV). Furthermore, since binding of Sp1 may alter the chromatin structure of a 
promoter we hypothesized that there may be a difference in chromatin modifications 
between the GG and AA genotype. In study IV treatment of B cells with HDACi 
resulted in an increase in IL-10 mRNA and this increase was somewhat larger for AA 
than GG genotype cells. Treatment with Butyrate and VPA resulted in a 4- and 3-fold 
increase in IL-10 transcription for the AA genotype cells compared to the GG 
genotype cells (fold increase 2 and 2). No increase in IL-10 mRNA transcription was 
found after treatment of the cells with TSA. Treatment with 5-aza, an inhibitor of 
DNA methyltransferases, resulted in a 5-fold increase in IL-10 transcription for AA 
genotype cells compared to a 4-fold increase for the GG genotype cells. These 
experiments were performed to demonstrate a possible influence of histone 
acetylation and DNA methylation on the regulation of IL-10 gene expression. 
 
To distinguish active chromatin from inactive chromatin in the IL-10 promoter 
region around the -1087 SNP we used the ChIP assay and antibodies for histone 
acetylation and methylation. The level of acetylation of histone H4 and methylation of 
histone H3 were found to be more pronounced in LPS-stimulated B cells from 
subjects with the GG genotype cells than in AA genotype cells (38%±5% and 
40%±11%, respectively). The AA genotype had a somewhat larger (7%±5%) increase 
in acetylation of histone H3 compared to the GG genotype. For the un-stimulated 
cells the corresponding numbers of fold increase for the GG genotype cells compared 
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to AA genotype cells were 88%±4% for acetylation of H3 and 66%±11% for 
methylation of H3. For the detection of acetylated histone H4 the AA genotype had a 
36%±19% higher fold increase compared to the GG genotype. Overall, LPS-
stimulation resulted in an 89%±1% fold increase for all antibodies. 
 
Three CpG sites upstream of the -1087 SNP were identified. Sequencing of the 
amplicon confirmed the previously identified sequence of the IL-10 promoter region. 
Bisulfite sequencing, HRM and gel electrophoresis analysis of the three CpGs distal of 
the -1087 site indicated that these CpGs were methylated in DNA from peripheral 
blood and gingival tissue samples from both GG and AA genotype subjects. 
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Main findings 
 
The transcription factors PU.1 and Spi-B bound to the region around the -1087 
position in the IL-10 promoter, while the Sp1 transcription factor only bound to the 
G-allele of the -1087 SNP. 
 
LPS-stimulation resulted in a larger increase in IL-10 and Sp1 gene expression in B 
cells with GG than in B cells with AA genotypes of the -1087 SNP. 
 
Sp1 was present in B cells in periodontitis lesions and subjects with the GG genotype 
exhibited larger proportions of Sp1-positive cells and expressed larger amounts of Sp1 
mRNA and protein in the lesion than AA genotype subjects. 
 
Epigenetic modifications influenced IL-10 gene expression and differences in 
epigenetic modifications in the promoter region were found between GG and AA 
genotype subjects. 
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 Concluding remarks 
 
In the present thesis functional aspects on the -1087 A to G nucleotide transition in 
the IL-10 promoter were studied. In particular, the identification of transcription 
factors, differences in transcription factor binding and the influence of transcription 
factor binding on the IL-10 gene expression were assessed. In addition, the presence 
of Sp1 in periodontitis lesions and epigenetic modifications of the IL-10 promoter 
were evaluated.  
 
In study I we identified three transcription factors binding to the region around -1087 
in the  IL-10 promoter  in vitro. The  transcription  factors  PU.1 and  Spi-B  bound at 
-1087 in both the G- and the A-allele, while Sp1 only  bound when  there was a  G at 
-1087. To our knowledge, this was the first report on Sp1 binding to -1087 in the 
human IL-10 promoter. Previous research has shown that the transcription factor 
PU.1 is able to bind at this site in human monocytic THP1 cells (Reuss et al. 2002). 
The -1087 A-allele matches the PU.1 core motif, while the -1087 G-allele differs. The 
authors therefore suggested that PU.1 has an optimal binding affinity for the A-allele 
and that this binding inhibits gene expression. However, the results in the EMSAs in 
Study I indicated that Sp1 had a higher binding affinity for this site than PU.1 and 
Spi-B. It may therefore be suggested that Sp1 rather than PU.1 and Spi-B is the key 
factor for the regulation of promoter activity for the GG genotype. These findings 
were further supported by the results of the co-transfection experiments in the SL2 
cells where transfection with increasing amount of Sp1 expression vector resulted in a 
corresponding increase in IL-10 promoter activity. This increase was larger for the G-
allele than the A-allele. Using the B cell line DG75 we showed that transfection with 
the GCC construct after LPS-stimulation resulted in a higher promoter activity than 
transfection with the ACC construct. LPS-stimulation of THP1 cells has previously 
been shown to result in a larger promoter activity for the GCC promoter construct 
compared to the ACC reporter construct (Reuss et al. 2002). However, a study on 
transfection of an un-stimulated EBV infected B cell line resulted in a larger 
transcriptional activity for the A-allele compared to the G-allele (Rees et al. 2002). 
Taken together, these results indicate that the -1087 SNP is important in the 
regulation of LPS-induced IL-10 gene expression.  
 
In study II, we further investigated the difference in transcription factor binding in vivo 
in B cell lines established from  subjects with either  the GG or AA  genotype for the 
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-1087 SNP. The results confirmed our previous findings  that Sp1 only  bound to the 
-1087 G-allele.  
 
Stimulation of B cells with LPS resulted in a larger increase in IL-10 and Sp1 mRNA 
transcription for the GG than AA genotype cells. The -1087 A/G polymorphism has 
previously been shown to influence the regulation of IL-10 gene expression but the 
results were inconclusive. Turner et al. (1997) reported that subjects negative for the 
A-allele had a higher IL-10 production than subjects positive for the A-allele. Similar 
results were presented by Hoffmann et al. (2001) and in study II of the present series. 
However, in a study by Yilmaz et al. (2005) LPS-stimulation of peripheral blood 
mononuclear cells revealed no difference in IL-10 production between AA and GG 
genotype subjects. Eskdale et al. (1999) compared the IL-10 secretion in relation to 
haplotypes and found that the A-allele was associated with higher IL-10 production 
than the G-allele. The authors suggested that the reason for the conflicting results 
between studies may relate to the experimental model including types of cells and 
stimuli.  
 
LPS-associated IL-10 expression was previously demonstrated to be associated with 
larger inter-individual variations compared to EBV-infection of the cells and 
stimulation using dibutyryl-cAMP (Mörmann et al. 2004). It was suggested that 
intracellular infectious agents, like EBV, regulate IL-10 through a pathway 
independent of the low- and high producer haplotypes. EBV infects primary B cells in 
the mucosal lymphoid tissue, and this infection induces the B cell to produce high 
amounts of IL-10. This IL-10 production may contribute to the immortalization of the 
B cells in vitro (Babcock 1998; Burdin et al. 1993). 
 
The decrease in IL-10 expression following Sp1 siRNA transfection in study II is in 
accordance with results presented by Chanteux et al. (2007). They reported that 
treatment of cells with the Sp1 inhibitor Mithramycin resulted in a decrease in nuclear 
Sp1 activation and an almost complete inhibition of LPS-induced IL-10 production at 
mRNA and protein level. The decrease in IL-10 transcription in study II was 
somewhat larger for the GG genotype cells compared to the AA genotype cells. It 
may be suggested that activation of MAPkinase pathways and the subsequent 
activation of Sp1 is essential in LPS-induced IL-10 production. 
 
In summary, the results presented in study I and II indicate that Sp1 has an important 
function in the regulation of IL-10 during the response to inflammatory signals and 
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that the -1087 A/G SNP influences IL-10 gene expression by altering the binding 
pattern of transcription factors.  
 
The reported findings on high levels of IL-10 and B cells in periodontitis lesions, 
together with the observations made in study II on a corresponding increase in Sp1 
and IL-10 gene expression in B cells after LPS-stimulation, suggest a possible 
influence of Sp1 in periodontitis lesions. Thus, in study III we assessed the amount of 
Sp1 in lesions from subjects with severe, generalized periodontitis and found a larger 
amount of Sp1 in lesions from GG genotype subjects compared to AA genotype 
subjects. Reports on the presence of Sp1 in tissues are predominantly from the field 
of cancer research. It was reported in several studies that Sp1 was strongly expressed, 
or even over-expressed, in tumor tissues, while in normal tissues Sp1 was absent 
(Jiang et al. 2008; Zhang et al. 2005). Using the threshold for Sp1 over-expression as 
defined by Jiang et al. (2008), the results presented in study II show an over-
expression of Sp1 for both the A-allele and the G-allele for -1087. It has been 
demonstrated that Sp1 is an important factor in inflammation and the regulatory 
function of Sp1 does not only involve IL-10. The LPS-induced NFκB binding to the 
IL-6 promoter is enhanced by Sp1 and the result is a more rapid response to 
inflammatory stimuli (Kang et al. 1996). Sp1 is also involved in the regulation of the 
TNF-α induction of protein A20 (Ainbinder et al. 2002), and in the maintenance of 
the basal TLR2 promoter activity in human epithelial cells (Furuta et al. 2008). In 
addition, the periodontal pathogen P.gingivalis is recognized by TLR2/1 and CD14. 
This interaction results in an activation of ERK1/2 (Krauss et al. 2010), providing an 
additional role of Sp1 in periodontitis. 
 
The results in study III also revealed a larger amount of IL-10 mRNA in periodontitis 
lesions from GG genotype subjects than in AA genotype subjects. The presence of 
IL-10 in periodontitis lesions has been reported in several studies (Aramaki et al. 1998; 
Lappin et al. 2001; Yamazaki et al. 1997), and a recent study demonstrated that 
periodontitis subjects with the GG genotype for the -1087 polymorphism had a larger 
amount of IL-10 positive cells in periodontitis lesions than subjects with the AA 
genotype (Donati et al. 2008). The larger IL-10 mRNA expression in study III 
corresponded to a similar larger Sp1 mRNA for GG than AA genotypes. The reason 
for this association of larger mRNA expression for the -1087 IL-10 GG genotype is 
presently not understood. 
 
In summary, study III is to our knowledge, the first report on the presence of Sp1 in 
periodontitis lesions. While the results indicate a possible role for Sp1 in periodontitis 
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further research on the Sp1 signaling pathways is needed to elucidate the role of Sp1 
in the inflammatory processes of periodontitis. 
 
In study IV, it was demonstrated that different epigenetic modifications of DNA and 
histones influence IL-10 gene expression. Differences between genotypes were found 
for acetylation of both histone H3 and H4, and for methylation of histone H3. 
 
To investigate whether epigenetic mechanisms can regulate IL-10 gene expression, B 
cells from subjects with either the GG or AA genotype were treated with HDAC 
inhibitors and the DNA methylation inhibitor 5-aza. Although TSA did not affect IL-
10 expression, the increase in IL-10 expression after treatment with VPA, Butyrat and 
5-aza indicated that epigenetic modifications influence IL-10 gene expression in B 
cells. The effect of Butyrate and 5-aza is in accordance with previous studies (Dong et 
al. 2007; Park et al. 2007; Säemann et al. 2000). Little is known of the effect of VPA on 
IL-10 gene expression. In a study on autism a decrease in IFN-γ/IL-10 ratio in mice 
exposed to VPA was found (Schneider et al. 2008). The reason for the larger IL-10 
increase after treatment with HDACi and 5-aza for the AA genotype compared to the 
GG genotype found in study IV is not clear. Vincent et al. (2008) reported that the 
expression of the human mucin gene MUC4 was found to increase after TSA and 5-
aza treatments in non-producing and low producing cells. While TSA inhibited 
expression in high producing cells, 5-aza was found to have no affect on high 
producing cells.  
 
In study IV, the acetylation of histones around -1087 was investigated using the ChIP 
assay and antibodies against acetylation of histone H3 and H4, respectively. Un-
stimulated cells that produced small amounts of IL-10 were acetylated to a smaller 
degree at both H3 and H4 than LPS-stimulated cells, in which the IL-10 promoter 
and gene expression were more active. The increase in methylation of histone H3 lys 
4 was associated with a more open chromatin in the -1087 region, which indicates a 
more active transcription. Since differences were found between the GG and AA 
genotype cells it may be suggested that the -1087 SNP influences the chromatin 
structure by alterations in transcription factor binding.  
 
The effect of methylation on Sp1 binding may be gene specific and depend on the 
strength of the Sp1-DNA interaction and on the sequence of the Sp1 site in the 
promoter (Vincent et al. 2008). It was reported that Sp1 binding to DNA could 
influence both acetylation and DNA methylation. Studies have shown that Sp1 can 
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bind and activate transcription even when the site is methylated (Höller et al. 1988). 
Therefore, we wanted to investigate if the binding of Sp1 influenced the methylation 
pattern at the -1087 site in the IL-10 promoter in GG and AA genotypes. We 
identified three CpG sites distal of the -1087 SNP and evaluated their methylation 
pattern in DNA from blood cells and gingival tissue. The results showed no 
differences in methylation of the CpGs between genotypes or between blood and 
tissue samples. Sp1 binding may be inhibited by methylation of adjacent CpG sites or 
methylation of the outer C (Clark et al. 1997; Zhu et al. 2003). However, since the 
three CpGs identified in the present series were located at a certain distance from the 
-1087 SNP (-1194, -1197 and -1227) it is unlikely that the G to A transition at -1087 
influences the methylation of these CpGs. Previous research on DNA methylation of 
the IL-10 promoter revealed 8 CpG sites in the proximal part of the promoter. It was 
demonstrated that the two most proximal CpGs at -185 and -110 differ most between 
IL-10 producing and non-producing cell lines (Szalmás et al. 2008). These findings 
show that the degree of methylation differs between CpGs in a promoter and that the 
promoter activity may be affected differently. In the study by Ehrlich et al. (1982) the 
authors reported on differences in DNA methylation between different cell types and 
tissues. The DNA methylation in a specific tissue did not differ between individuals 
and the DNA methylation did not always correlate with the level of transcription.  
 
The IL-10 promoter does not contain any CpG islands and only a few CpG sites. The 
bisulfite modification changes the unmethylated cytosines into uracils, which during 
the PCR are amplified as thymines. In the IL-10 promoter region investigated in the 
present series of studies the absence of CpG islands resulted in an AT-rich sequence 
after PCR amplification. The AC repeat downstream presented additional limitation 
for the primer design. This resulted in a short amplicon of 59 bp and sensitive 
sequencing methods were therefore required. Since the 3 identified CpG sites were 
not part of a CpG island, difficulties in the interpretation of the controls were 
obvious. Additional research is needed on the methylation level of these CpGs in 
regards to genotypes and tissue types. 
 
In summary, in study IV epigenetic modifications were found to influence IL-10 gene 
expression. Differences were found between the GG and AA genotypes, indicating a 
possible influence of the -1087 SNP on epigenetic modifications in the IL-10 
promoter region. 
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The present series of studies has shown that the GG genotype for the -1087 IL-10 
gene polymorphism is associated with a higher IL-10 production than the AA 
genotype and that the binding of Sp1 to the G-allele influences the IL-10 gene 
expression. The results presented indicate an important role for Sp1 in the regulation 
of IL-10. The presence of Sp1 in periodontitis lesions suggests that Sp1 may influence 
the regulation of immune signaling in periodontitis. Further studies on the interaction 
between Sp1 and other factors involved in IL-10 regulation are needed to elucidate 
the role of Sp1 in the transcription process and in the regulation of other pro- and 
anti-inflammatory cytokines.  
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